drugset

drugset / Trial / NCT02672839

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

NCT02672839 ↗

Phase 1 Completed 12 enrolled Ligand Pharmaceuticals Medpace, Inc. · collab

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare relative oral bioavailability of a capsule formulation of LGD-6972 to a solution formulation of LGD-6972.

Timeline

Start: 2016-02
Primary completion: 2016-05
Completion: 2016-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LGD-6972	Small molecule	15 mg	Oral

Indications